Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
The health care technology company Concert Genetics (formerly NextGxDx; Nashville, Tenn.) recently released its third edition of…
By Sean McSweeney bio
The year 2018 is slated to be much brighter for molecular diagnostic labs as PAMA fee schedules show a higher payment rate and amount for many cancer genomics and…
From - Diagnostic Testing & Emerging Technologies
Despite existing recommendations, blood culture is overused in patients with suspected, uncomplicated cellulitis, according to a research letter published…
From - Diagnostic Testing & Emerging Technologies
As might be expected, there has been rapid growth in genetic test availability and spending on these tests since 2014. But, comprehensive new collaborative analysis conducted by…
From - Diagnostic Testing & Emerging Technologies
Expanded next-generation sequencing-based carrier screening improves detection of rare and novel pathogenic variants even in…